Gossamer Bio CEO Faheem Hasnain at #BIO22 (J.T. MacMillan Photography)

Gos­samer lays off 25% of em­ploy­ees, cuts all pro­grams ex­cept PAH drug

As Gos­samer Bio goes all in on its lead drug for pul­monary ar­te­r­i­al hy­per­ten­sion (PAH), it’s cut­ting off all oth­er clin­i­cal and pre­clin­i­cal pro­grams — as well as 25% of its staff.

Fa­heem Has­nain, the co-founder, CEO and chair of Gos­samer, called the re­struc­tur­ing de­ci­sion dif­fi­cult in a press re­lease but “a nec­es­sary step to fo­cus the or­ga­ni­za­tion on ac­tiv­i­ties which max­i­mize the po­ten­tial of ser­a­lu­tinib,” the PAH can­di­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.